Moderna Bags $176M Award From Rapid Response Partnership Vehicle To Boost mRNA-Based Pandemic Influenza Vaccines Development
Portfolio Pulse from Benzinga Newsdesk
Moderna has received a $176 million award from the Rapid Response Partnership Vehicle to advance the development of mRNA-based pandemic influenza vaccines.
July 02, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna has been awarded $176 million by the Rapid Response Partnership Vehicle to enhance its mRNA-based pandemic influenza vaccines development.
The $176 million award will provide significant funding for Moderna's mRNA-based pandemic influenza vaccine development, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100